Cereno Scientific

Update in progress

CRNO-B.ST (Stockholm)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Cereno Scientific AB (publ) is a clinical stage biotechnology company focused on therapies for cardiovascular and pulmonary diseases, based in Gothenburg, Sweden. Its lead candidate CS1 is in Phase II for pulmonary arterial hypertension and acts as an epigenetic HDAC inhibitor with pressure-reducing, anti-inflammatory, anti-fibrotic, anti-thrombotic effects. CS014 is in Phase I for cardiovascular and pulmonary diseases and idiopathic pulmonary fibrosis; CS585 is a preclinical IP receptor agonist for rare thrombotic diseases. The company collaborates with the University of Michigan on preclinical programs for CS585 and CS014 and with Abbott for CardioMEMS HF System.

Company score

Sentiment: 0.51; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.17; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.29; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive